1 February 2022
Highlight on Active Biomarkers 🤝
Since its inception in 2011, ACTIVE BIOMARKERS is supporting
multiple biopharmaceutical companies in their preclinical and clinical research programs 🔬
Based on state-of-the-art technologies, ACTIVE BIOMARKERS provides its partners with multiple fit-for-purpose bioanalytical solutions.
ACTIVE BIOMARKERS is operating in multiple therapeutic areas, particularly in neurodegeneration & neuroinflammation, immune-oncology, inflammatory & autoimmune disorders and infectious diseases
They also support the clinical development of multiple immunotherapeutic products.
Furthermore, ACTIVE BIOMARKERS is actively investing in RD programs to develop, optimize and validate innovative biomarkers / endpoint assays addressing medical needs 🧬
